Mr. Mogutov joined the board of Ovoca in June 2006 and became Chairman in 2008. Mr. Mogutov qualified as an Engineer-Physicist in 1979 from the Moscow physics-chemistry institute and in 1984 was awarded a PhD from the Institute of Molecular Genetics specialising in Molecular Biology. Mr. Mogutov has led a number of businesses across a range of sectors including life science, chemical, heavy industries, financial services and natural resources. Mr. Mogutov’s recent experience in the life science sector including acting as chairman for Biomed-Mecnikov, a biotechnology company focused on the production of biopharmaceutical medicines based on recombinant proteins and Pharmapark, a biotechnology company focused on developing, manufacturing and promoting biopharmaceuticals in Russia. In 2006 Mr. Mogutov founded Bioprocess Capital Partners LLP, a trust manager of the Bioprocess Capital Ventures which is focused on investing in innovative biotech projects. Mr. Mogutov is fluent in Russian and English.
Chief Executive Officer
Mr. Golovanov joined Ovoca as a corporate advisor in 2007 and moved to be the manager of the Company’s Russia representative office in 2009. He was appointed as Chief Executive Officer of Ovoca in May 2012. During his time at Ovoca he played a major role in the development and subsequent sale of the Goltsovoye silver deposit and the Olcha gold deposit. He has extensive experience in the development of venture businesses in Russia, as well as working experience at leading Russian enterprises, such as Gazprombank and Vneshekonombank. Mr. Golovanov holds a JD, Moscow State Law Academy, Moscow, Russia and an MBA from Duke University’s Fuqua School of Business, NC, USA. He also holds a Russian qualification certificate corresponding to the position of a head, or a controller, or a specialist in an organisation which carries out securities management and manage investment funds, unit investment funds and non-governmental pension funds. Mr. Golovanov is fluent in Russian and English.
Mr. Colindres is an experienced medical practitioner and pharmaceutical executive, having worked with GlaxoSmithKline plc (“GSK”) in a number of senior roles since 2007. Mr. Colindres is currently Vice President, Global Medical Affairs Lead for Zoster with GSK and has previously held roles with GSK in Panama, Brazil and Belgium during his career with the company. Prior to joining GSK, Mr. Colindres was a physician in the United States and Brazil and previously held roles in public health in the United States and El Salvador. Mr. Colindres holds an MBA from Duke University’s Fuqua School of Business, NC, USA, an MD from University of North Carolina School of Medicine, Chapel Hill, NC, USA and a Masters of Public Health from University of North Carolina School of Public Health, Chapel Hill, NC, USA. Mr. Colindres is fluent in Spanish and English.
Mr. McCutcheon joined the board of Ovoca as a Non-Executive Director in January 2009 and moved into the CEO position in December 2009 before stepping down in April 2012 and becoming again a Non-Executive Director. Prior to Ovoca, Mr. McCutcheon was a partner at DBM Capital Partners, an investment manager and corporate finance boutique specializing in natural resources. He also worked at several investment banks such as Bear Stearns, Aton Capital and Pioneer Investments as an award-winning equity analyst and as an investment banker. Currently, Mr. McCutcheon is president of Wealth Minerals Ltd, a TSX-V company developing lithium assets for clean energy applications. He also provides management and business development services to natural resource, technology and aerospace firms. Mr. McCutcheon holds a BA, cum laude, from Columbia College, New York and an MBA in Finance from Columbia Business School. Mr. McCutcheon is fluent in English and Russian.
Mr. Wiltshire is an experienced senior pharmaceutical and biotechnology executive with over 20 years of international experience. He currently serves as the CEO of Hematherix LLC, a company he founded in 2015 to develop a first-in-class, early stage recombinant blood protein. Between 2008 and 2015, he was the founder/owner of IPT Bioconsulting, which provided strategic advice to early and mid-stage biotechnology and pharmaceutical companies. Mr. Wiltshire previously served in number of senior positions with Pfizer between 1998 and 2008, including as head of business transactions and investments within The Pfizer Incubator LLC. Prior to joining Pfizer, Mr. Wiltshire worked with Eli Lilly and Company between 1993 and 1998. Mr. Wiltshire holds an MA in Engineering from the University of Cambridge in the UK and an MBA from the Darden Graduate School, University of Virginia, US.
Mr. Skoptsov joined the board of Ovoca in June 2006 and served as the Company’s chief executive officer from 2006 to 2009. Mr. Skoptsov was part of the Bioprocess Group team that owned and ran OAO “United Machinery Plants” (OMZ). He also played an active part in natural resource development prior to Ovoca. He was the Chairman of OAO Pervaya Gornorudnaya Companiya from 2001–2005, a zinc-lead asset developer. He was also the Chairman of OAO Volganeft from 2000 to 2004, a mid-tier oil producer in Russia which was sold to Russneft. He was part of the group that vended into Ovoca Gold plc 100% of OAO Ajax – Goltsovoye. Mr. Skoptsov holds a BA, cum laude, from Moscow State University, Moscow, Russia. Mr. Skoptsov is fluent in Russian and English.